Search Results
-
Extra income and cancer risk factors
Cancer disproportionately impacts persistently impoverished communities. A federal grant unites Stanford Medicine, UC Davis and UCSF to study income supplementation and cancer risk factors.
-
Stanford Medicine gives to the community
Stanford Medicine donated more than $950 million in funds and services during the 2022 fiscal year, focusing on access to health care, housing and nutrition.
-
Race linked to child abuse reports
Over-reporting of Black children and under-reporting of white children as suspected abuse victims suggests systemic bias from medical providers, Stanford Medicine research shows.
-
Hepatitis C treatment low
Antiviral medicine eliminates hepatitis C in 97% of patients, but Stanford Medicine researchers and colleagues find that many don’t receive the treatment.
-
Improving end-of-life care for kids
Research into medical decisions for children with terminal illnesses can be improved by sensitively tapping the expertise of families who have lost a child, according to Stanford Medicine experts.
-
What to know about polio
The first polio case in the U.S. since 2013 emerged in July, and cases have increased abroad. Yvonne Maldonado answers questions about the virus and its impacts.
-
Autism is different in girls’ brains
Girls with autism differ in several brain centers compared with boys with the disorder, suggesting gender-specific diagnostics are needed, a Stanford study using artificial intelligence found.
-
Piecemeal e-cigarette policies bad for youth
Flavored disposable e-cigarettes attractive to young users proliferated after the most recent round of FDA policy announcements, negating the policies’ intended effects, a Stanford study found.
-
Office of Child Health Equity launched
Pediatrician Lisa Chamberlain will lead a new office that promotes pediatric health equity via research, community engagement and health policy.
-
Breast cancer mutations don’t lower survival rates
Newly diagnosed breast or ovarian cancer patients who carry common cancer-associated mutations have similar or better short-term survival rates than those with no mutations, researchers report.